1. Introduction {#sec0005}
===============

Worldwide, hepatocellular carcinoma (HCC) is one of the most lethal cancers, causing ∼745,000 deaths annually [@bib0005]. The prognosis for HCC is poor with a 5-year survival rate of \<5%. Surgical resection remains the primary therapy [@bib0010], [@bib0015]. However, the incidence of tumor recurrence is \>50% [@bib0020]. Symptoms of HCC typically do not appear until a late stage. Only 10--20% of HCC tumors are diagnosed early enough for effective surgery [@bib0025], [@bib0030], [@bib0035]. Poor prognosis is due in part to a lack of effective and accurate early diagnostic methods, limiting treatment options. Patients with cirrhosis are at increased risk for developing HCC, and represent an important surveillance population [@bib0040], [@bib0045], [@bib0050]. New imaging techniques may improve the sensitivity and accuracy for early detection of HCC. Photoacoustic imaging is an emerging imaging modality that uses the combination of light for absorption and sound for emission. Compared with ultrasound, it offers higher resolution and capability for targeted detection.

Targeted imaging may improve specificity for detection of HCC. The epidermal growth factor receptor (EGFR) pathway plays an essential role in cell proliferation, survival and migration and its altered activity has been implicated in the development and growth of many tumors including HCC [@bib0055], [@bib0060], [@bib0065]. In previous studies, EGFR has been found to be overexpressed in 40--70% of HCC [@bib0070], [@bib0075], [@bib0080], [@bib0085], [@bib0090], [@bib0095], most likely contributing to aggressive growth characteristics [@bib0100], [@bib0105], metastasis formation, and resistance to therapy [@bib0085], [@bib0110], [@bib0115], [@bib0120]. The EGFR inhibitor Gefitinib has been found to significantly reduce the incidence of HCC in an animal model [@bib0075]. EGFR is also overexpressed by other cancers, including lung [@bib0125], breast [@bib0130], pancreas [@bib0135], head and neck [@bib0140], and esophagus [@bib0145]. EGFR represents an attractive target for biologics (such as peptide and affibody [@bib0150] or antibodies in applications such as tumor-targeted imaging and therapy.

We have previously developed a peptide specific for EGFR [@bib0155]. Peptides have small size and low molecular weight that result in ideal pharmacokinetic properties for deep tissue imaging. Compared with bulky monoclonal antibodies, peptides provide an attractive alternative for visualizing tissue targets that would otherwise be difficult to penetrate or access [@bib0160]. Peptides clear rapidly from non-target tissues, resulting in reduced background. Peptides can be structurally altered to improve stability against proteolytic degradation, increase circulatory half-life, and enhance capillary permeability [@bib0165]. All of these attributes promote deep penetration into tissue and more effective targeting. Here, we aim to demonstrate the use of a peptide specific for EGFR to target HCC tumors in a pre-clinical xenograft model.

2. Methodology {#sec0010}
==============

2.1. Synthesis of photoacoustic imaging agents {#sec0015}
----------------------------------------------

Monomeric linear peptides QRHKPRE, hereafter QRH\*, and its scrambled control PEHKRRQ, hereafter PEH\*, (molecular weight = 1334.73 for both peptides) were synthesized with linker GGGSK using standard Fmoc-mediated solid-phase synthesis [@bib0155]. The C-terminal lysine was incorporated as Fmoc-Lys (ivDde)- OH, and the N-terminal amino acid was incorporated with Boc protection to avoid unwanted Fmoc removal during deprotection of the ivDde moiety prior to labeling. The ivDde side chain protecting group was removed with 5% hydrazine in DMF (3 × 10 min) with continuous shaking at room temperature (RT). QRH\*-Cy5.5 and PEH\*-Cy5.5 were synthesized by coupling QRH\* and PEH\* with water soluble sulfo-Cy5.5- N-hydroxysuccinimide ester (Lumiprobe LLC) respectively overnight with N,N-diisopropylethylamine, followed by HPLC purification. The final purity was confirmed by analytical C18-column. Further characterization was performed with exact mass measurement by Q-TOF (Agilent Technologies) mass spec with ESI (Waters Inc) detection. After lyophilization, the peptides were stored at −80 °C and dissolved in water at a concentration of 300 μM before injection. The absorption spectrum was measured at 100 μM concentration with a UV--vis spectrophotometer in the 500--900 nm range (NanoDrop 2000, Thermo Scientific). Molecular graphics and analyses of the peptides were performed with the UCSF Chimera package (v. 1.10.2, University of California, San Francisco).

2.2. HCC xenograft tumor {#sec0020}
------------------------

Human HCC cells SK-Hep1, HepG2, and Hep3B were purchased from the ATCC (Manassas, VA) and cultured in Eagle\'s Minimum Essential Medium (EMEM). All cells were cultured at 37 °C in 5% CO~2~, and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Western blot was performed using a 1:1000 dilution of primary polyclonal rabbit anti-EGFR antibody (\#2232S, Cell Signaling Technology) per manufacturer instructions. Loading was controlled with a 1:500 dilution of monoclonal mouse anti-β-tubulin (\#32-2600, Invitrogen). SK-Hep1 cells were diluted in growth factor reduced (GFR) Matrigel Matrix (Corning), and injected into one flank of female (to avoid male dominance within a cage) nude athymic mice (nu/nu, Jackson Laboratory) at 4--6 weeks of age with weight between 20 and 25 g. ∼5 × 10^6^ cells were implanted per mouse. Anesthesia was induced and maintained via a nose cone with inhaled isoflurane mixed with oxygen at a concentration of 2--4% at a flow rate of ∼0.5 L/min for all in vivo animal experiments.

2.3. Confocal fluorescence microscopy {#sec0025}
-------------------------------------

∼10^3^ cells were grown on coverslips to ∼80% confluence, washed once with PBS, and incubated with 5 μM QRH\*-Cy5.5 and PEH\*-Cy5.5 for 10 min at RT. The cells were then washed 3X in PBS, fixed with 4% PFA for 5 min, washed with PBS, and then mounted on glass slides with ProLong Gold reagent containing DAPI (Invitrogen). Confocal microscopy (Leica Inverted SP5X) was performed using a 63X oil-immersion objective. Fluorescence intensities from 5 cells in 2 independent images were quantified using custom Matlab (Mathworks) software.

2.4. Ultrasound imaging {#sec0030}
-----------------------

2D ultrasound (US) images were collected from each xenograft tumor using a portable ultrasound scanner (SonixTablet, Ultrasonix, Analogic Corp.) designed for small animal imaging. During image acquisition, the mice were placed on a heated stage. Anesthesia was induced and maintained with 2% isofluorane (Fluriso; MWI Veterinary Supply Co.). Warmed (37 °C) ultrasound gel (Aquasonic 100, Parker Laboratories) was applied to the tumors. The ultrasound transducer (40 MHz) was used in B-mode, and translated along the length and width of the tumor. 3 images were taken in each direction to calculate tumor volume. Each image had a 12 × 12 mm^2^ field of view with an in-plane pixel resolution of 50 × 50 μm^2^ [@bib0170].

Ellipsoid volumes were estimated using πabc/6, where a, b, and c are dimensions measured from the US images. a is defined by the largest dimension in the sagittal plane, while b is the value perpendicular to a. c is the parameter orthogonal to both a and b in the transverse plane. Each measurement was performed 3 times [@bib0175].

2.5. MRI imaging {#sec0035}
----------------

Tumor size was confirmed with MRI images collected with a 7T horizontal bore small animal MRI system (SGRAD 205/120/HD/S, Agilent Technologies) using a volume-based transmit/receive quadrature radio frequency coil with an inner diameter of 3.5 cm. The animals were given an intra-peritoneal (i.p.) injection of macrocyclic gadolinium chelate (Gadoteridol, ProHance) at a dose of 2.5 mmol Gd/kg body weight. Body temperature was maintained at 37 °C by blowing hot air into the magnet through a feedback control system. ∼12--15 min after injection of gadolinium, transverse T1-weighted sections were acquired with a scout sequence in 3 orthogonal axes to identify tumor location. A 256 × 128 matrix was obtained in 5 min by conventional spin-echo multi-slice pulse sequence using repetition time (TR) = 8.5 ms, echo time (TE) = 2.6 ms, average = 2, in-plane field of view (FOV) = 35 × 35 mm^2^, 25-mm slab thickness of 1 mm thick interleaved slices with no gap in between. Tumor volume was assessed with the freehand region of interest (ROI) function of NIH Image J software. Areas were measured on each MRI slice (1 mm thickness) and added together to reconstruct the 3D tumor volume.

2.6. Photoacoustic images of HCC xenograft tumor in vivo {#sec0040}
--------------------------------------------------------

We used a photoacoustic tomography system (Nexus128, Endra Inc.) that provides laser excitation at 7 ns pulses, 20 Hz repetition rate, 25 mJ/pulse, and wavelength range 680--950 nm. Ultrasound is collected by 128 unfocused 3 mm diameter transducers with 5 MHz center frequency arranged in a helical pattern in a hemispherical bowl filled with water, [Fig. 1](#fig0005){ref-type="fig"}A. A transparent imaging tray located above the transducers was used to contain anesthetized animals. The console also includes data acquisition/reconstruction software, servo motors to rotate the bowl, and a temperature monitor. We optimized the imaging protocol to collect 120 views with 10 pulses/view, covering an imaging volume of 25 × 25 × 25 mm^3^ with a voxel size of 280 μm^3^. Each dataset required ∼2 min for acquisition. The animals were administered QRH\*-Cy5.5 at 300 μM in 250 μL (75 nmol), and placed inside the tray with the subcutaneous tumor positioned inside a water-filled dimple to couple the ultrasound signal, [Fig. 1](#fig0005){ref-type="fig"}B. We acquired images with λ~ex~ = 680 nm at 0, 1, 3, 6, 12, and 24 h. A preliminary study was performed to determine wash out time after injecting either peptide (target or control), and whether the order of injection affected the photoacoustic signal level.

The 3D image was reconstructed after completion of imaging using data acquired from all 128 transducers at each view with a back-projection algorithm [@bib0180]. This algorithm corrects for pulse to pulse variations in laser intensity and small changes in temperature that affect the velocity of acoustic waves in water. The reconstructed raw data was analyzed using Osirix 6.5.2 software (Pixmeo) to generate a maximum intensity projection (MIP) image, which was converted to a color map using Matlab (R2013a, ver 8.1, Mathworks) software. Imaging was repeated with PEH\*-Cy5.5 and Cy5.5 alone (dye without peptide) 48 h later in the same animals after the target peptide had cleared. 3D visualization of the reconstructed photoacoustic signals was performed using Amira software (ver 5.4.3, FEI Corporation), including volume rendering technique (VRT) with specular shading and color map for physics. The alpha value was set at 0.7 in order to reveal blood vessel structures underneath the tissue surface.

2.7. Validation of EGFR binding ex vivo with immunohistochemistry {#sec0045}
-----------------------------------------------------------------

Resected tumor and normal liver were fixed in 10% buffered formalin and paraffin embedded. 10 μm thick serial sections were cut and deparaffinized. Briefly, sections were incubated in xylene 3X for 3 min, washed with 100% ethanol 2X for 2 min, and washed with 95% ethanol 2X for 2 min. Rehydration was performed by washing the sections twice in dH~2~O for 5 min. Antigen unmasking was performed using Protease XXV (\#AP-9006-002, Thermo Scientific) at 1 mg/mL in PBS buffer with pH 7.4 and digested for 15 min at 37 °C. The sections were washed 3X in dH~2~O for 3 min, and then incubated in 3% H~2~O~2~ in H~2~O for 10 min. The sections were washed 3X in dH~2~O for 2 min and in PBST for 5 min. Blocking was performed with DAKO protein blocking agent (X0909, DAKO) for 1 h at RT. We used 1:250 dilution of monoclonal mouse anti-EGFR antibody (clone 111.6, Thermo Scientific). The sections were incubated overnight in primary antibody at 4 °C and then washed in PBS 3X for 5 min. A 1:200 dilution of secondary antibody (goat anti-mouse) was added to each section and incubated for 30 min at RT. The secondary antibody solution was removed by washing 3X with PBS for 5 min. Premixed Elite Vectastain ABC reagent (Vector Labs) was added to each section and incubated for 30 min at RT. The sections were washed 3X in PBST for 5 min, and developed with 3,3′-diaminobenzidine substrate. The reaction was monitored for 1 min, and then quenched by immersing the slides in dH~2~O. Hematoxylin was added as a counterstain for ∼20 s, and the sections were dehydrated in increasing concentrations of ethyl alcohol (70%, 80%, 2X at 95%, 2X at 100%). Coverslips were attached using permount mounting medium (\#SP15-100, Fisher) in xylene. Serial sections were processed for histology (H&E). Controls were prepared using secondary antibody, Elite Vectastain ABC reagent, Vector Labs and 3,3′-diaminobenzidine (without primary anti-EGFR antibody).

2.8. Validation of EGFR binding ex vivo with immunofluorescence {#sec0050}
---------------------------------------------------------------

Resected tumor and normal liver (n = 24 mice) were formalin-fixed, paraffin embedded and cut in 10 μm thick sections. Deparaffinization, rehydration and antigen unmasking was performed, as described previously. Blocking was performed with DAKO protein blocking agent (X0909, DAKO) for 1 h at RT. Sections were then incubated with 5 μM QRH\*-Cy5.5 in 2% BSA for 10 min at RT. The sections were washed 3X with PBS and mounted with Prolong Gold reagent containing DAPI (Invitrogen). Confocal microscopy was performed using λ~ex~ = 670 and 405 nm for Cy5.5 and DAPI, respectively, at 63X magnification. Fluorescence intensities were measured from 3 randomly positioned boxes with dimensions of 20 × 20 μm^2^. Regions that showed intensity saturation were avoided.

2.9. Image analysis {#sec0055}
-------------------

The mean photoacoustic intensity in the target region was measured using the circular ROI function on 2D MIP photoacoustic images in Osirix 6.5.2 software with tumor dimensions measured using US (diameter of circle provided by arithmetic mean of dimensions a and c). The mean background was measured from the adjacent annulus with equal area. The target-to-background (T/B) ratio was calculated. Prism software (v6.02, GraphPad) was used to plot all data.

3. Results {#sec0060}
==========

3.1. Photoacoustic contrast agent specific for EGFR {#sec0065}
---------------------------------------------------

QRHKPRE (black) was labeled on the C-terminus with Cy5.5 (red) via a GGGSK linker (blue), [Fig. 2](#fig0010){ref-type="fig"}A. Using a structural model, we found a binding energy of E~t~ = −554.81 kcal/mol for docking to EGFR (1IVO) [@bib0155]. By comparison, we found E~t~ = −535.37 kcal/mol for the scrambled (control) peptide, PEH\*-Cy5.5, [Fig. 2](#fig0010){ref-type="fig"}B. In the model, QRH\*-Cy5.5 binds to amino acids 230--310 of EGFR (domain 2), [Fig. 2](#fig0010){ref-type="fig"}C. The absorption spectra of QRH\*-Cy5.5 and PEH\*-Cy5.5 at 100 μM concentration in water shows a peak at λ~abs~ = 677 nm, [Fig. 2](#fig0010){ref-type="fig"}D. We purified the Cy5.5-labeled peptides to \>95% on HPLC. This result was confirmed on mass spectrometry. We found a molecular weight of 2232.88 g/mol, which agrees with the expected value, Fig. S1A,B. 3D surface structures of labeled targeting and scrambled control peptides are shown in Fig. S2A,B.

3.2. Specific binding to EGFR overexpressed in HCC cells {#sec0070}
--------------------------------------------------------

On confocal microscopy, we assessed binding of QRH\*-Cy5.5 and PEH\*-Cy5.5 to human HCC cells SK-Hep1, Hep3B, and HepG2 cells that express different levels of EGFR, respectively. For QRH\*-Cy5.5, we observed different strengths of binding to the cell surface (arrows), [Fig. 3](#fig0015){ref-type="fig"}A--C. Minimal binding was observed for PEH\*-Cy5.5 (control) to all cells, [Fig. 3](#fig0015){ref-type="fig"}D--F. We measured significantly greater fluorescence intensity from QRH\*-Cy5.5 compared to PEH\*-Cy5.5 for SK-Hep1 and Hep3B cells but not for HepG2, [Fig. 3](#fig0015){ref-type="fig"}G. Also, the QRH\*-Cy5.5 versus PEH\*-Cy5.5 differences were significantly larger for SK-Hep1 and Hep3B than for HepG2. Western blot of cells is shown, [Fig. 3](#fig0015){ref-type="fig"}H.

3.3. Ultrasound and MRI monitoring of tumor growth {#sec0075}
--------------------------------------------------

SK-Hep1 cells were inoculated subcutaneously in n = 8 nude mice at 4--6 weeks of age. Tumor size was monitored weekly for 12 weeks. Representative images are shown with ultrasound (US), [Fig. 4](#fig0020){ref-type="fig"}A, and MRI, [Fig. 4](#fig0020){ref-type="fig"}B. A peak tumor volume (±SD) of 761 ± 160 and 936 ± 148 mm^3^ was found on US and MRI, respectively, [Fig. 4](#fig0020){ref-type="fig"}C. A correlation of R = 0.98 was found between tumor size on US and MRI, [Fig. 4](#fig0020){ref-type="fig"}D.

3.4. Photoacoustic images of HCC xenograft tumor in vivo {#sec0080}
--------------------------------------------------------

At 6 weeks post inoculation, representative photoacoustic images collected with λ~ex~ = 680 nm at 0, 1, 3, 6, 12, and 24 h after injection of 300 μM in 250 μL of QRH\*-Cy5.5 i.v. are shown as maximum intensity projection (MIP) images at a mean (±SD) depth of 8.1 ± 1.3 mm with range 0--1.8 cm below the skin surface. At this time, the tumors had reached a mean (±SD) size of 100 ± 23 mm^3^ by US. The tumors showed increased signal in a heterogeneous pattern with visible blood vessels, [Fig. 5](#fig0025){ref-type="fig"}A--F. Preliminary study (data not shown) confirmed wash out of either QRH-Cy5.5 or PEH-Cy5.5 from the animals' system occurred by 24 h post injection and no difference in signal intensity or pattern were associated to injection order. After 48 h when signal was no longer observed from the EGFR peptide, the PEH\*-Cy5.5 control peptide was administered in the same animal, [Fig. 5](#fig0025){ref-type="fig"}G--L. For additional control, images from HCC with Cy5.5 alone, [Fig. 5](#fig0025){ref-type="fig"}M--R, and from adjacent normal tissue with QRH\*-Cy5.5, [Fig. 5](#fig0025){ref-type="fig"}S, are shown. A volume rendered image of the tumor at 3 h post injection is shown (Video 1), [Fig. 5](#fig0025){ref-type="fig"}T.

3.5. Target-background (T/B) ratio of HCC on photoacoustic images {#sec0085}
-----------------------------------------------------------------

The photoacoustic intensity from the tumor (target) was measured using a circular ROI with diameter determined from US, and an adjacent annulus with area equal to that of the target ROI was used to measure background (white circles in [Fig. 5](#fig0025){ref-type="fig"}C). HCC tumors showed a higher T/B ratio for the EGFR peptide compared with that of the control peptide at each time point up to 24 h. Tumor uptake of QRH\*-Cy5.5 increased steadily after injection to a peak value at 3 h, [Fig. 6](#fig0030){ref-type="fig"}A. The T/B ratio then decreased over time to near baseline by 24 h. Meanwhile, non-tumor exhibited minimal uptake. The HCC image with Cy5.5 alone (no peptide) showed a small effect of tumor permeability and retention [@bib0185], [@bib0190]. Injection of Cy5.5 dye alone produced a peak T/B ratio of 1.30 ± 0.14 at 1 h post injection at tumor site. We measured a T/B ratio of 1.22 ± 0.14 at the tumor site and 1.05 ± 0.13 from adjacent normal tissue at 3 h respectively. Peak T/B ratios for the EGFR and control peptides at 3 h are shown, [Fig. 6](#fig0030){ref-type="fig"}B. The T/B ratios at each time point for individual mice are shown, Fig. S3.

3.6. Validation of EGFR peptide binding ex vivo {#sec0090}
-----------------------------------------------

On immunohistochemistry (IHC), we observed strong staining of EGFR in HCC tumors [Fig. 7](#fig0035){ref-type="fig"}A. On immunofluorescence (IF), strong signal from QRH\*-Cy5.5 is seen on the surface of tumor cells, [Fig. 7](#fig0035){ref-type="fig"}B. In normal mouse liver, a few lightly stained hepatocytes (arrow) can be seen surrounding the central vein (arrowhead) with IHC, [Fig. 7](#fig0035){ref-type="fig"}D. Minimal signal from QRH\*-Cy5.5 was seen in normal liver with IF, [Fig. 7](#fig0035){ref-type="fig"}E. Corresponding histology (H&E) of tumor and normal is shown, [Fig. 7](#fig0035){ref-type="fig"}C and F. We found the mean fluorescence intensity from HCC to be significantly greater than that of normal by 3.8-fold, [Fig. 7](#fig0035){ref-type="fig"}G. The corresponding ROC curve shows 92% sensitivity and 96% specificity for distinguishing HCC from normal liver with an area under curve of AUC = 0.97.

4. Discussion {#sec0095}
=============

Here, we demonstrate use of photoacoustic imaging to visualize HCC xenograft tumors in living mice with a peptide specific for EGFR. This peptide was used previously to collect fluorescence images endoscopically from mouse colonic adenomas with topical administration [@bib0155]. We now show that specific binding to EGFR can also occur with systemic administration. We used Cy5.5, a NIR fluorophore, to achieve good photoacoustic signal at a depth down to 1.8 cm with low background. We found peak uptake at 3 h post injection and clearance by ∼24 h. This time frame is significantly faster than most antibodies, which can take hours to home to the tumor and even longer to clear [@bib0195], [@bib0200].

Previous photoacoustic imaging studies have used endogenous contrast from hemoglobin and melanin [@bib0205], and others have relied on the enhanced permeability and retention (EPR) effect [@bib0210], [@bib0215]. These strategies are based on non-specific detection mechanisms. By comparison, use of a targeting moiety can improve tumor homing, increase signal, and improve contrast by tuning absorption to specific wavelengths [@bib0220]. The EPR effect can be variable and produce false positives in highly vascular tissues [@bib0185]. Photoacoustic imaging has been used with other molecular probes for targeted detection. An enzyme sensitive oligomer labeled with Atto-740 was used to detect furin-like activity [@bib0225]. DMSO was needed to improve solubility, and the oligomers were found to aggregate and form nanostructures that trapped the reporter molecule inside the cells. RGD peptides have been used to target integrins in tumor-associated blood vessels that arise from angiogenesis and metastasis, a finding that occurs at a late stage of tumor development [@bib0230], [@bib0235], [@bib0240], [@bib0245]. Antibodies labeled with gold nanoparticles have been used to image molecular targets, such as Her-2, EGFR, CXCR4 and LYVE-1 [@bib0250], [@bib0255], [@bib0260], [@bib0265], [@bib0270]. Antibodies are large in size, high in molecular weight, and have long circulatory half-lives [@bib0275]. They also have limited ability to extravasate from the vasculature, diffuse within tumors, penetrate deeply, and clear from interstitial space [@bib0275], [@bib0280]. All of these properties increase imaging background. Antibodies are also prone to immunogenicity that limits repetitive use [@bib0285].

Epidermal growth factor receptor (EGFR) is overexpressed in many cancers and promotes solid tumor growth [@bib0290]. Previous studies have targeted EGFR to improve imaging specificity, and have used metallic nanoparticles [@bib0260], [@bib0270], [@bib0295] and organic dyes [@bib0300], [@bib0305], [@bib0310] to generate contrast. Gold nanospheres [@bib0270], gold nanrods [@bib0315], silica-coated gold nanorods [@bib0320], and silver nanoplates [@bib0325] have been labeled with monoclonal EGFR antibodies to image cells overexpressing EGFR [@bib0330] with photoacoustic imaging. Targeted nanoparticles can be used as sensors to detect molecular interactions. EGFR-targeted gold nanospheres aggregate in endosomes after undergoing receptor-mediated endocytosis [@bib0335]. This results in plasmon coupling and a red shift in the absorption spectrum, which is detectable with photoacoustic imaging. Therefore, nanoparticles in the endosomes of cells overexpressing EGFR can be detected and distinguished from free nanoparticles in the tumor, which may have accumulated via the EPR effect [@bib0270]. The high cost and long circulatory time of antibodies as targeting moiety in imaging could potentially inhibit acceptance for clinical translation as a diagnostic tool. This motivates our present study to explore feasibility for use of a cost-efficient and fast acting EGFR targeting peptide.

Photoacoustic imaging is an emerging imaging modality that provides greater depth than optical methods and better resolution than ultrasound. We were able to visualize a large fraction of the volume of HCC tumors, and may be able to improve imaging depth with use of stronger labels, such as nanoparticles [@bib0340]. This method may be useful for evaluating the effect of drugs under development for tumor therapy. Previous studies has reported the ability of hybrid plasmonic contrast agent gold nanotube (GNT) to achieve picomolar sensitivity compared to nanomolar levels for conventional agents [@bib0180]. Moreover indocyanine green labeled with single walled carbon nanotubes (SWNT-ICG) can improve photoacoustic contrast by ∼300-fold [@bib0235]. This technique using non-ionizing radiation, and can be more cost-effective and easier to use than MRI, PET, and SPECT. The photoacoustic images were collected with a spatial resolution of 280 μm in all dimensions. By comparison, ultrasound at the same central frequency of 5 MHz without 3D data acquisition and image reconstruction can achieve 470 μm axial and ∼1--5 mm lateral resolution [@bib0345]. However, high-frequency linear-array-based micro-ultrasound platforms operating at frequencies of 30--70 MHz (compared to frequencies of 3--15 MHz for clinical ultrasound systems) can allow spatial resolution as high as 30-μm [@bib0350]. Nuclear imaging methods (PET and SPECT) have spatial resolution in the ∼1--2 mm range [@bib0220], [@bib0355]. Our in vivo images required long image acquisition and reconstruction times (∼2 min). Faster lasers and more efficient algorithms may enable real time image-guided surgery with a photoacoustic endoscope.

In this study, we used a version of Cy5.5 that has four additional hydrophilic ---SO~3~H groups ([Fig. 1](#fig0005){ref-type="fig"}A) to improve water solubility. With the previous fluorophore, we used a concentration of 100 μM, which was adequate for topical administration to detect pre-malignant disease in mouse colon [@bib0155]. In this study, we achieved a ∼3-fold greater concentration, and used systemic administration to deliver the peptide to a solid tumor. The higher dye solubility allowed for use of a volume that is tolerated by the animal. Because the peak absorption of Cy5.5 occurs below 700 nm, the imaging depth can be improved with organic dyes, such as ICG and Licor IRDye800 [@bib0245], [@bib0360], that absorb at longer wavelengths and avoids hemoglobin absorbance and minimizes tissue scattering. Moreover, nanoparticles have 3--10 times higher extinction coefficient than organic dyes [@bib0365], and can absorb more energy from light per mass density. Example of nanoparticles that can be used to label peptides for increased signal include iron oxide [@bib0230], gold nanorods [@bib0250], CuS [@bib0370], nanospheres [@bib0270], [@bib0375], carbon nanotubes [@bib0235], [@bib0380] and polymer nanoparticles [@bib0385], [@bib0390], [@bib0395], [@bib0400]. Metallic nanoparticles have very strong absorption that can also be used for photothermal therapy after tumor delivery [@bib0240], [@bib0405]. Carbon nanotubes are considered more bio-compatible [@bib0410], absorb over a broad spectrum [@bib0330], and possess superior photoacoustic signal strengths compared to metallic NPs. Polymer NPs can be more photostable than gold nanorods and photoacoustically brighter than carbon nanotubes with pulsed laser irradiation. Despite these advantages, nanoparticles are foreign bodies that can cause inflammation in liver [@bib0415], [@bib0420] and increase circulation time \[85\]. While prolonged circulation time of conventional nanoprobes may enhance targeted drug delivery [@bib0425], [@bib0430], peptides may offer advantages for improved deep tumor penetration and accumulation with reduced biodistribution to non-target tissues [@bib0435], [@bib0440]. Among nanomaterial-based agents already approved by the FDA [@bib0445], all but one of these agents are therapeutics [@bib0450]. On the other hand, nanoparticles have not received FDA approval for clinical imaging [@bib0455]. A smart or activatable nanoparticles with improved pharmacokinetic, tumor targeting and organ clearance properties, based on the use of natural, biodegradable polymers (dextran and heparin), is desired. Organic dyes have a benign toxicity profile [@bib0460] and pharmacokinetic characteristics are compatible with clinical translation.

The typical shape of tumor xenografts in this study was oblate ellipsoid with almost equal dimensions parallel to skin surface but much shorter in depth beneath the skin (i.e. b \< a ≈ c). Thus approximation of tumor area with circular ROI was adopted in PA signal intensity measurement for 2D MIP images. 3D volumetric quantification of PA images could potentially give a more accurate intensity measurement if an algorithm capable of defining arbitrary oblate ellipsoid as ROI and taking into account the illumination attenuation along tissue depth were available.

We used human SK-Hep1 cells that overexpress EGFR to introduce HCC xenograft tumors. This technique may produce higher levels of EGFR expression and less heterogeneity than that found in sporadic human HCC [@bib0465]. In the future, we will use patient derived xenograft (PDX) models that include stroma and better reflect clinically relevant EGFR expression levels [@bib0470] and tumor microenvironment [@bib0475]. PDX models can also be effective for evaluating new drugs [@bib0480], [@bib0485], [@bib0490]. Both subcutaneous [@bib0475], [@bib0495], [@bib0500] and orthotopic [@bib0505] PDX models of HCC have been developed by other groups. Also, detection of multiple targets simultaneously may be needed to address the genetic diversity of HCC. Our imaging system can use a broad range of wavelengths (680--950 nm). This spectrum covers the absorption peaks of many NIR dyes (Cy5.5, ICG, IRDye800) and nanoparticles (Au, SWNT and Co [@bib0250], [@bib0340], [@bib0380]). A panel of peptides labeled in spectrally distinct regions may be needed to achieve high detection sensitivity in the clinic. Adapting functionalized nanoparticles for excitation at different wavelengths would allow for multiplexed imaging to be performed [@bib0510].
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The following are Supplementary data to this article:Fig. S1 Mass spectrometry of Cy5.5-labeled peptides. Experimental mass-to-charge (*m*/*z*) ratios for (A) QRH\*-Cy5.5 and (B) PEH\*-Cy5.5 were found to be 2233.89 (with one C-13), and agreed with the expected values.Fig. S2 3D structures of labeled targeting and scrambled control peptides. Structural differences were observed between targeting and scrambled control peptides. Cy5.5 dye was labeled on C-terminal of each 7-mer peptide and the sulfonated benzo-fused indolenine rings are marked with arrows. The N-terminals of peptides where the 7-mer sequences begin are denoted with arrow heads. Both the overall shapes and local chemical environments are different in the two probes. Color code: grey-C; white-H; red-O; blue-N; yellow-S.Fig. S3 Individual T/B ratio plots at each time point.Video 1 3D volumetric photoacoustic image of EGFR expression in HCC xenograft tumor. Video is shown of volume rendered photoacoustic images collected from HCC xenograft tumor at 3 h post injection of 250 μL 300 μM of QRH\*-Cy5.5.
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![Schematic of imaging system. (A) Laser pulses at λ = 680 nm (green) are absorbed by the tumor to produce acoustic waves that are detected by 128 ultrasound transducers arranged in a helical pattern. Water between the imaging tray and transducer array provides acoustic coupling. (B) Photograph of live animal under anesthesia with tumor positioned inside a dimple in the center of the tray. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr1){#fig0005}

![Photoacoustic contrast agent specific for EGFR. (A) Chemical structure of QRHKPRE peptide (black) with GGGSK linker (blue) and Cy5.5 fluorophore (red), hereafter QRH\*-Cy5.5. (B) Scrambled control peptide PEHKRRQ, hereafter PEH\*-Cy5.5. (C) QRH\*-Cy5.5 was found on the structural model (1IVO) to bind EGFR domain 2. (D) Absorbance spectra of Cy5.5-labeled peptides shows peak at λ~ex~ = 677 nm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](gr2){#fig0010}

![Specific peptide binding to EGFR overexpressed in HCC cells. On confocal microscopy, we observed fluorescence at the surface (arrow) of (A) SK-Hep1, (B) Hep3B, and (C) HepG2 cells that have different levels of EGFR expression after incubation with QRH\*-Cy5.5. (D--F) Minimal signal is observed with PEH\*-Cy5.5 for all cells. (G) Quantified measurements show that QRH\*-Cy5.5 has significantly greater intensities than PEH\*-Cy5.5 on binding to SK-Hep1 and Hep3B cells (5.72 and 6.57 fold-change, *P* = 1.63 × 10^−5^ and 1.05 × 10^−5^, respectively). A non-significant difference was found for HepG2 cells (1.02 fold-change, *P* = 0.91). Differences between QRH\*-Cy5.5 and PEH\*-Cy5.5 for SK-Hep1 and Hep3B were significantly greater than that for HepG2 (5.63 and 6.46 fold-change, *P* = 1.25 × 10^−4^ and 8.12 × 10^−5^, respectively). We fitted two-way ANOVA models with terms for 3 cell lines, 2 peptides, and their interactions to log-transformed data. Measurements are an average of 5 randomly chosen cells on 2 slides for each condition. (H) Western blot shows EGFR expression levels for HCC cells.](gr3){#fig0015}

![Monitoring of tumor growth. Representative images of subcutaneous HCC tumor (arrow) at 6 weeks post-inoculation are shown with (A) ultrasound (US) and (B) MRI (T1 weighted contrast-enhanced). (C) Mean (±SD) dimensions for n = 8 tumors from US and MRI images from post inoculation weeks 1--12 are shown. (D) Positive correlation of R = 0.98 was found for tumor size measured with US and MRI.](gr4){#fig0020}

![Photoacoustic images of HCC tumor in vivo. Representative MIP images at depth of 1.8 cm were collected at 0, 1, 3, 6, 12 and 24 h after injection with (A--F) QRH\*-Cy5.5 and (G--L) PEH\*-Cy5.5 are shown. In panel (C), inner circle represents regions-of-interest (ROI) used to measure signal from tumor, and adjacent annulus with equal area was used to measure background. (M--R) Images of tumor with injection of Cy5.5 alone (no peptide) at 0--24 h post injection. (S) Image of normal area at 3 h after QRH-Cy5.5 injection. (T) 3D reconstruction of tumor images.](gr5){#fig0025}

![Target-background (T/B) ratio of HCC on photoacoustic images. (A) Images collected over time show peak tumor QRH\*-Cy5.5 uptake at 3 h after i.v. injection. T/B ratio of 2.25 ± 0.25 was significantly greater than 1.31 ± 0.36 for PEH\*-Cy5.5, *P* = 1.2 × 10^−3^ by paired *t*-test. Injection of Cy5.5 dye alone produced peak T/B ratio, 1.30 ± 0.14, at 1 h post injection at tumor site. T/B ratio of 1.22 ± 0.14 at tumor site and 1.05 ± 0.13 at adjacent normal tissue were observed at 3 h respectively. Wash out of probe was observed within 24 h. (B) Individual data points for T/B ratios at 3 h are shown.](gr6){#fig0030}

![Ex vivo validation of EGFR binding. (A) Immunohistochemistry (IHC) with anti-EGFR antibody shows increased reactivity to HCC. A nest of tumor cells with large irregular round nuclei (arrows) and infiltrating blood vessels lined with flattened endothelial cells (arrowhead) can be seen. (B) Immunofluorescence (IF) with QRH\*-Cy5.5 shows binding to surface of HCC cells. Fluorescence intensities were measured from sets of 3 (dashed white) boxes with dimensions of 20 × 20 μm^2^. (C) Corresponding histology (H&E) of tumor. (D) IHC of normal mouse hepatocytes show few lightly stained cells (arrows) surrounding the central vein (arrowhead). (E) IF of normal mouse liver shows minimal signal. (F) Histology of normal mouse liver shows lobule with central vein (arrowhead) surrounded by radially aligned plates of hepatocytes. (G) Mean (±SD) fluorescence intensities for HCC (n = 24 tumors) are significantly higher than that for normal liver (n = 24), 27.8 ± 11.5 versus 7.37 ± 3.80 by 3.77-fold, *P* = 3.4 × 10^−10^ by paired *t*-test. (H) ROC curve shows 92% sensitivity and 96% specificity with area under curve (AUC) of 0.97 for distinguishing HCC from normal liver using QRH\*-Cy5.5.](gr7){#fig0035}
